Pursuant to the provisions of Regulation 33 and other applicable provisions of SEBI we wish to inform you that the Board of Directors (the ''Board'') of ADS Diagnostic Limited (''the Company'') ....
Awaiting price reaction for this filing.
ADS Diagnostic Limited's board approved unaudited standalone financial results for the quarter and nine months ended 31 December 2025. Total income for Q3 FY26 stood at ₹545.98 lakhs versus ₹260.21 lakhs in Q3 FY25, more than doubling year-on-year. For the nine-month period, total income rose to ₹2,445.03 lakhs from ₹1,275.55 lakhs in 9M FY25, a jump of roughly 92%. Net profit after tax for 9M FY26 came in at ₹95.40 lakhs (up ~30% from ₹73.40 lakhs), while Q3 FY26 PAT was largely flat at ₹19.81 lakhs versus ₹19.19 lakhs. EPS for 9M FY26 was ₹4.35 versus ₹3.35. Statutory auditor V.N. Purohit & Co. issued an unqualified limited review report, with no qualifications or going-concern flags.
Strong top-line growth in 9M FY26 is positive for the stock, but the modest single-digit growth in Q3 PAT despite more-than-doubled revenue points to margin pressure that investors should watch. A clean auditor's review and ~30% 9M profit growth support fundamentals.